Peptide
Contacts
Fournisseurs
Peptides
Experts
Recherche
Apprendre
Communauté
Actualités
Outils
Search...
⌘K
Se connecter
S'inscrire
Ouvrir le menu
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]
RESEARCH
Semaglutide in Alcohol Use Disorder [NCT07949474]
RESEARCH
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
NEWS
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
RESEARCH
Semaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]
RESEARCH
Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]
RESEARCH
Semaglutide in Alcohol Use Disorder [NCT07949474]
RESEARCH
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
NEWS
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
RESEARCH
Semaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]
RESEARCH
Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]
Pour des fins de recherche uniquement.
Déclaration complète →
Tous les contacts
Influencer
Jeff Bland
𝕏
▶
W